ambrey-geneticsambry-geneticsbmi-healthcareBMIbrca-test-ukbrcabupacardio-dxcolordowndownloadfacebookforwardhalio-dxhca-healthcareHCAhearticon-burgericon-closeicon-githubicon-twitterinvitae-horizontalinvitae-verticalnanostringnuffield-healthnuffieldoncodnaoncomarkribbonskylineveracytevideovitality coloricon-github
TumorNext-Lynch (8 genes) logo

Is TumorNext-Lynch the right test right for you?

If you have been diagnosed with colorectal or endometrial cancer with abnormal MSI and/or IHC results, this test can help inform key treatment decisions.

It looks at both tumour and hereditary gene mutations to rule out or confirm Lynch syndrome (a particular type of colorectal cancer) to provide accurate information about therapies that could help you, particularly a treatment called PD-LI or PD-1 immunotherapy.

Ask your clinician how you can get this test – and about our other tests which look at aspects of colorectal cancer to find out which one is right for you.


Why?Close tab

Would PD-LI or PD-1 immunotherapy help you?

Colorectal cancer is the third most common cancer in men and women and Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is a type of inherited cancer syndrome associated with a genetic predisposition to different cancer types.

Knowing whether you have Lynch syndrome and understanding particular gene mutations within your tumour is critical to decision-making about whether PD-LI or PD-1 immunotherapy, effectively harnessing the power of your body’s own immune system to treat your cancer is possible.

Hereditary risk of other cancers

This test can also indicate if you have a hereditary risk of developing other cancers – and therefore what steps you need to take for further screening or monitoring.

You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 1270 699021.

How?Close tab

What do I need to do?

This test is an analysis of 8 specific genes in the DNA of your tumour tissue. You will have had a biopsy before you received your cancer diagnosis, and we can use the sample taken at that time so you may not need an additional medical procedure to take this test.

ProcessClose tab

Through your clinician

This test is only available with authorisation from your clinician, who will receive your test results directly.

Step 1.  Purchase and permission

Buy the test. You will receive an email asking you to confirm that you have authorised ELG to be given a sample of your tumour tissue.

Step 2. Collection of sample

We will contact your clinician directly and organise the collection of your sample and delivery to the laboratory.

Step 3: Analysis and reporting

Your sample will be analysed and a report will be generated, usually within three to four weeks of receipt of your sample in the laboratory.

Step 4: Results

Your clinician will receive a comprehensive test report of the 8 genes in your DNA and particularly any mutations which indicate whether or not PD-LI or PD-1 immunotherapy treatment could help you.

The report will also indicate if mutations have been identified which are associated with the hereditary risk of developing other cancers, so that you and members of your family can take action to protect your health in future.

CliniciansClose tab

Is TumorNext-Lynch the right test for your patient?

When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy, you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumour and germline mutations, giving you clearer information to better guide treatment decisions.

When to consider testing

  • Patients with colorectal or endometrial cancer who are suspicious for Lynch syndrome due to abnormal MSI/IHC
  • Patients with abnormal MSI and/or IHC results, with no germline Lynch syndrome gene mutations found
Test Description
  • Tumour and germline paired analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM
  • Microsatellite instability (MSI)
  • MLH1 promoter hypermethylation analysis.
  • Option to add on BRAF (V600E), NRAS, and KRAS targeted analysis
  • The following tumour types will be accepted (assuming all other specimen requirements are met): colorectal, endometrial, ovarian, Fallopian tube, primary peritoneal, small bowel, stomach, pancreas, appendiceal, gallbladder, bladder, ureter, renal pelvis, sebaceous cancer, prostate, and colorectal polyps with high grade dysplasia.

This test is provided by:

Ambry Genetics

Frequently asked questions

Do I need a doctor to authorise this test?
Yes, your doctor will need to provide the sample required for this test.
Will my health insurance cover the cost of this test?
Many health insurance plans cover the cost of genetic testing – check with your provider to find out if it is in your policy.
How soon do I get my results?
Usually within three to four weeks of receipt of your sample in the laboratory.
How accurate is the test?
Ambry follows advanced laboratory procedures and ensures quality control to deliver accurate results you can trust.